

Peter J Hoskin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1592381/publications.pdf>

Version: 2024-02-01

302
papers

26,498
citations

9786

73
h-index

6996

154
g-index

343
all docs

343
docs citations

343
times ranked

20792
citing authors

#	ARTICLE	IF	CITATIONS
1	Bayesian methods in palliative care research: cancer-induced bone pain. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, e5-e9.	1.6	3
2	Exclusive 3D-brachytherapy as a good option for stage-I inoperable endometrial cancer: a retrospective analysis in the gynaecological cancer GEC-ESTRO Working Group. <i>Clinical and Translational Oncology</i> , 2022, 24, 254-265.	2.4	7
3	Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 681-693.	0.8	14
4	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	1.6	40
5	Risk Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Analysis From the EMBRACE-I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1177-1189.	0.8	6
6	Bladder function after conservative surgery and high-dose rate brachytherapy for bladder-prostate rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29574.	1.5	6
7	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	13.7	173
8	GEC-ESTRO ACROP prostate brachytherapy guidelines. <i>Radiotherapy and Oncology</i> , 2022, 167, 244-251.	0.6	28
9	Prognostic Implications of Uterine Cervical Cancer Regression During Chemoradiation Evaluated by the T-Score in the Multicenter EMBRACE I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 379-389.	0.8	7
10	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29
11	ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. <i>Radiotherapy and Oncology</i> , 2022, 173, 197-206.	0.6	28
12	The impact of an educational tool in cervix image registration across three imaging modalities. <i>British Journal of Radiology</i> , 2022, 95, .	2.2	0
13	Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial. <i>Radiotherapy and Oncology</i> , 2022, 173, 77-83.	0.6	3
14	Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature. <i>Molecular Medicine Reports</i> , 2022, 26, .	2.4	2
15	Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.	8.4	35
16	ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. <i>Radiotherapy and Oncology</i> , 2022, 173, 240-253.	0.6	34
17	Update on the systematic review/meta-analysis of uncomplicated bone metastases treated with external beam radiation. <i>Radiotherapy and Oncology</i> , 2022, 174, 109-110.	0.6	3
18	Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results. <i>Radiotherapy and Oncology</i> , 2021, 154, 214-219.	0.6	59

#	ARTICLE	IF	CITATIONS
19	Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 161-173.	0.8	16
20	Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 688-700.	0.8	31
21	Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 158, 300-308.	0.6	23
22	Risk factors for urethral stricture following external beam radiotherapy and HDR brachytherapy for prostate cancer. Brachytherapy, 2021, 20, 302-306.	0.5	2
23	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncology, The, 2021, 22, 246-255.	10.7	73
24	Developing Tumor Radiosensitivity Signatures Using LncRNAs. Radiation Research, 2021, 195, 324-333.	1.5	10
25	Double the Target Volumes. International Journal of Radiation Oncology Biology Physics, 2021, 109, 846.	0.8	0
26	4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2021, 22, 332-340.	10.7	51
27	MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncology, The, 2021, 22, 538-547.	10.7	268
28	Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study. Radiotherapy and Oncology, 2021, 157, 24-31.	0.6	6
29	Dosimetry of local failure with single dose 19ÂGy high-dose-rate brachytherapy for prostate cancer. Radiotherapy and Oncology, 2021, 157, 93-98.	0.6	4
30	A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer. British Journal of Cancer, 2021, 125, 85-93.	6.4	6
31	Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 158, 312-320.	0.6	33
32	High dose simultaneous integrated boost for node positive cervical cancer. Radiation Oncology, 2021, 16, 92.	2.7	9
33	Response to Yuce Sari et al.. Radiotherapy and Oncology, 2021, 158, 323-324.	0.6	0
34	Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy. Radiotherapy and Oncology, 2021, 158, 184-190.	0.6	16
35	Lost in application: Measuring hypoxia for radiotherapy optimisation. European Journal of Cancer, 2021, 148, 260-276.	2.8	21
36	Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial. Radiotherapy and Oncology, 2021, 159, 67-74.	0.6	7

#	ARTICLE	IF	CITATIONS
37	Brachytherapy for locally advanced cervical cancer: A survey of UK provision of care and support. <i>Radiotherapy and Oncology</i> , 2021, 159, 60-66.	0.6	4
38	Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastasesâ€”A Phase 2, Randomized Controlled Trial Within a Prospective Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 368-370.	0.8	3
39	Can Hypofractionation and Immune Modulation Coexist?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 742-744.	0.8	1
40	Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review. <i>Radiotherapy and Oncology</i> , 2021, 163, 55-67.	0.6	9
41	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. <i>Cancer Treatment Reviews</i> , 2021, 98, 102206.	7.7	30
42	Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1407-1415.	0.8	33
43	Hypofractionation: less is more?. <i>Oncotarget</i> , 2021, 12, 1729-1733.	1.8	0
44	Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomographyâ€”Directed Therapy for Early-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3591-3601.	1.6	21
45	Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 168-177.	0.8	24
46	Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 681448.	2.8	17
47	Impact of hypoxia on cervical cancer outcomes. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1459-1470.	2.5	17
48	Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis. <i>Radiotherapy and Oncology</i> , 2021, 163, 150-158.	0.6	12
49	The effect of hypoxia on PD-L1 expression in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 1271.	2.6	14
50	Magnetic resonanceâ€”guided radiation therapy: A review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 163-177.	1.8	104
51	External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 525-533.	0.8	26
52	Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer. <i>Clinical Oncology</i> , 2020, 32, 259-265.	1.4	17
53	Treatment of classical Hodgkin lymphoma in young adults aged 18â€”30Â years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012). <i>British Journal of Haematology</i> , 2020, 189, 128-132.	2.5	2
54	A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer. <i>British Journal of Radiology</i> , 2020, 93, 20190760.	2.2	8

#	ARTICLE	IF	CITATIONS
55	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€”An International Collaborative Multistakeholder Effortâ€“. European Urology, 2020, 77, 223-250.	1.9	132
56	Radical External-Beam Radiotherapy in Combination With Intracavitary Brachytherapy for Localized Carcinoma of the Cervix in Sri Lanka: Is Treatment Delayed Treatment Denied?. JCO Global Oncology, 2020, 6, 1574-1581.	1.8	5
57	The role of palliative radiotherapy in bladder cancer: a narrative review. Annals of Palliative Medicine, 2020, 9, 4294-4299.	1.2	8
58	Sarcopenia in cancer: Risking more than muscle loss. Technical Innovations and Patient Support in Radiation Oncology, 2020, 16, 50-57.	1.9	75
59	Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic â€” Rapid Review. Clinical Oncology, 2020, 32, 347-353.	1.4	10
60	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 2020, 38, 3024-3031.	1.6	26
61	Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines. Radiotherapy and Oncology, 2020, 150, 30-39.	0.6	53
62	Radiobiologically derived biphasic fractionation schemes to overcome the effects of tumour hypoxia. British Journal of Radiology, 2020, 93, 20190250.	2.2	2
63	Comparison of radiographer interobserver image registration variability using cone beam CT and MR for cervix radiotherapy. British Journal of Radiology, 2020, 93, 20200169.	2.2	6
64	A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate 125I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial. Journal of Contemporary Brachytherapy, 2020, 12, 1-5.	0.9	7
65	A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. BMC Cancer, 2020, 20, 198.	2.6	25
66	Colorectal cancer: summary of NICE guidance. BMJ, The, 2020, 368, m461.	6.0	25
67	Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study. Radiotherapy and Oncology, 2020, 143, 95-100.	0.6	19
68	Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 316-324.	0.8	50
69	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 148, 102861.	4.4	29
70	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. Blood Advances, 2020, 4, 203-206.	5.2	15
71	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Blood, 2020, 136, 16-18.	1.4	2
72	Excess dose-related parameters (Vex, Rex, and iRex): novel predictors and late toxicity correlations in cervical cancer image-guided adaptive brachytherapy. Journal of Contemporary Brachytherapy, 2020, 12, 441-453.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Practical brachytherapy solutions to an age-old quandary. Technical Innovations and Patient Support in Radiation Oncology, 2020, 16, 39-47.	1.9	1
74	Clinical trials targeting hypoxia. British Journal of Radiology, 2019, 92, 20170966.	2.2	24
75	New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer. Nature Reviews Urology, 2019, 16, 523-538.	3.8	21
76	Single Fraction High-Dose-Rate Brachytherapy: Too Good to Be True?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1054-1056.	0.8	5
77	Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis. Radiotherapy and Oncology, 2019, 141, 56-61.	0.6	71
78	Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. European Urology, 2019, 76, 69-70.	1.9	3
79	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 809-818.	0.8	23
80	Organ preservation in bladder cancer: an opportunity for truly personalized treatment. Nature Reviews Urology, 2019, 16, 511-522.	3.8	31
81	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. Journal of Clinical Oncology, 2019, 37, 1732-1741.	1.6	38
82	Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2019, 104, 895-902.	0.8	62
83	Hypoxia and angiogenic biomarkers in prostate cancer after external beam radiotherapy (EBRT) alone or combined with high-dose-rate brachytherapy boost (HDR-BTb). Radiotherapy and Oncology, 2019, 137, 38-44.	0.6	6
84	Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. Radiotherapy and Oncology, 2019, 134, 185-190.	0.6	41
85	Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 2084.	7.4	71
86	Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies. International Journal of Radiation Oncology Biology Physics, 2019, 103, 887-894.	0.8	39
87	Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: An analysis from the EMBRACE study. Radiotherapy and Oncology, 2018, 127, 440-448.	0.6	30
88	Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: A report from the EMBRACE study. Radiotherapy and Oncology, 2018, 127, 449-455.	0.6	23
89	Bladder cancer and the National Cancer Data Base: New insight or misinformation?. Cancer, 2018, 124, 1105-1107.	4.1	5
90	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 295-309.	10.7	426

#	ARTICLE	IF	CITATIONS
91	Focal boost to residual gross tumor volume in brachytherapy for cervical cancer—A feasibility study. Brachytherapy, 2018, 17, 181-186.	0.5	3
92	The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clinical and Translational Radiation Oncology, 2018, 9, 48-60.	1.7	415
93	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine, 2018, 31, 182-189.	6.1	132
94	ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiotherapy and Oncology, 2018, 127, 49-61.	0.6	157
95	Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. European Urology, 2018, 73, 427-435.	1.9	84
96	The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. British Journal of Haematology, 2018, 180, 52-59.	2.5	8
97	Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases. Quality of Life Research, 2018, 27, 1089-1098.	3.1	32
98	Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial. Radiotherapy and Oncology, 2018, 126, 541-546.	0.6	2
99	Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity. Anticancer Research, 2018, 38, 5423-5427.	1.1	11
100	Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiotherapy and Oncology, 2018, 127, 423-430.	0.6	54
101	Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. Radiotherapy and Oncology, 2018, 129, 499-506.	0.6	10
102	Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 2018, 29, iv166-iv191.	1.2	461
103	Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. Radiotherapy and Oncology, 2018, 127, 431-439.	0.6	69
104	Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 418-422.	1.3	124
105	Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review. Radiotherapy and Oncology, 2017, 122, 323-331.	0.6	28
106	A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. Clinical Cancer Research, 2017, 23, 4761-4768.	7.0	107
107	A review of patterns of practice and clinical guidelines in the palliative radiation treatment of uncomplicated bone metastases. Radiotherapy and Oncology, 2017, 124, 38-44.	0.6	27
108	Treat All Known Disease. International Journal of Radiation Oncology Biology Physics, 2017, 98, 494.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. New England Journal of Medicine, 2017, 377, 338-351.	27.0	1,315
110	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica, 2017, 102, 1748-1757.	3.5	38
111	A restatement of the natural science evidence base concerning the health effects of low-level ionizing radiation. Proceedings of the Royal Society B: Biological Sciences, 2017, 284, 20171070.	2.6	68
112	The evolution of brachytherapy for prostate cancer. Nature Reviews Urology, 2017, 14, 415-439.	3.8	106
113	Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiotherapy and Oncology, 2017, 124, 56-60.	0.6	75
114	How should radiation oncologists interpret the ASTRO evidence-based guideline and ASTRO Choosing Wisely campaign for the treatment of uncomplicated bone metastases?. Practical Radiation Oncology, 2017, 7, 13-15.	2.1	10
115	Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. Annals of Palliative Medicine, 2017, 6, 125-142.	1.2	49
116	The optimism surrounding stereotactic body radiation therapy and immunomodulation. Chinese Clinical Oncology, 2017, 6, S9-S9.	1.2	9
117	Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiotherapy and Oncology, 2016, 120, 441-446.	0.6	252
118	Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Radiotherapy and Oncology, 2016, 120, 412-419.	0.6	198
119	High dose rate brachytherapy for prostate cancer: Standard of care and future direction. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 81-82.	1.4	0
120	Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiotherapy and Oncology, 2016, 120, 434-440.	0.6	236
121	Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiotherapy and Oncology, 2016, 120, 428-433.	0.6	527
122	High dose rate brachytherapy for prostate cancer: Standard of care and future direction. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 77.	1.4	0
123	The Use of Angiogenic and Hypoxia Biomarkers to Predict the Benefit from Dose Escalation Using External Beam Radiotherapy Plus a High Dose-Rate Brachytherapy Boost Compared to External Beam Radiotherapy Alone in Localized Prostate Cancer. Brachytherapy, 2016, 15, S74-S75.	0.5	1
124	Image Guided Brachytherapy in Cervical Cancer: A Comparison between Intracavitary and Combined Intracavitary/Interstitial Brachytherapy in Regard to Doses to HR CTV, OARs and Late Morbidity - Early Results from the Embrace Study in 999 Patients. Brachytherapy, 2016, 15, S21.	0.5	14
125	Bone Metastases. Medical Radiology, 2016, , 317-336.	0.1	0
126	Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate, 2016, 76, 905-916.	2.3	58

#	ARTICLE	IF	CITATIONS
127	The dosimetric impact of air in vaginal vault brachytherapy. Brachytherapy, 2016, 15, 832-838.	0.5	7
128	Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer. Radiotherapy and Oncology, 2016, 120, 293-299.	0.6	8
129	Doseâ€effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiotherapy and Oncology, 2016, 118, 160-166.	0.6	153
130	Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life. Supportive Care in Cancer, 2016, 24, 1617-1623.	2.2	16
131	Squamous-cell carcinoma of the anus: progress in radiotherapy treatment. Nature Reviews Clinical Oncology, 2016, 13, 447-459.	27.6	32
132	High dose rate brachytherapy for prostate cancer: Standard of care and future direction. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 66-72.	1.4	10
133	Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain. Journal of Clinical Oncology, 2016, 34, 550-556.	1.6	58
134	A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study. Radiotherapy and Oncology, 2016, 118, 122-130.	0.6	39
135	Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1088-1098.	0.8	77
136	Predictive model for survival in patients having repeat radiation treatment for painful bone metastases. Radiotherapy and Oncology, 2016, 118, 547-551.	0.6	9
137	Recommendations for Radiotherapy Technique and Dose in Extra-nodal Lymphoma. Clinical Oncology, 2016, 28, 62-68.	1.4	4
138	Prostate: Low Dose Rate Brachytherapy. Medical Radiology, 2016, , 299-317.	0.1	1
139	Loss of expression of the tumour suppressor gene <i>AIMP3</i> predicts survival following radiotherapy in muscleâ€invasive bladder cancer. International Journal of Cancer, 2015, 136, 709-720.	5.1	24
140	IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastases. Radiotherapy and Oncology, 2015, 116, 10-14.	0.6	22
141	Use of bladder dose points for assessment of the spatial dose distribution in the posterior bladder wall in cervical cancer brachytherapy and the impact of applicator position. Brachytherapy, 2015, 14, 252-259.	0.5	15
142	Cancer induced bone pain. BMJ, The, 2015, 350, h315-h315.	6.0	89
143	Stereotactic Body Radiotherapy for Spinal and Bone Metastases. Clinical Oncology, 2015, 27, 298-306.	1.4	63
144	Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.6	11

#	ARTICLE	IF	CITATIONS
145	Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era” Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). <i>European Urology</i> , 2015, 67, 1028-1038.	1.9	340
146	Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 1598-1607.	27.0	619
147	Hypoxia dose painting in prostate and cervix cancer. <i>Acta Oncologica</i> , 2015, 54, 1259-1262.	1.8	25
148	A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv197.	6.3	29
149	International survey of the treatment of metastatic spinal cord compression. <i>Journal of Radiosurgery and SBRT</i> , 2015, 3, 237-245.	0.2	4
150	Dosimetric analysis of urethral strictures following HDR 192Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 410-413.	0.6	15
151	Risk of Premature Menopause After Treatment for Hodgkin’s Lymphoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	48
152	Impact of Reirradiation of Painful Osseous Metastases on Quality of Life and Function: A Secondary Analysis of the NCIC CTG SC.20 Randomized Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3867-3873.	1.6	32
153	Optimal source distribution for focal boosts using high dose rate (HDR) brachytherapy alone in prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 121-125.	0.6	14
154	Protons and more: state of the art in radiotherapy. <i>Clinical Medicine</i> , 2014, 14, s61-s65.	1.9	18
155	Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the <scp>UK</scp>. <i>BJU International</i> , 2014, 113, 748-753.	2.5	17
156	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 738-746.	10.7	433
157	4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. <i>Lancet Oncology</i> , The, 2014, 15, 457-463.	10.7	191
158	Re-irradiation for painful bone metastases “ A systematic review. <i>Radiotherapy and Oncology</i> , 2014, 110, 61-70.	0.6	48
159	Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique. <i>Radiotherapy and Oncology</i> , 2014, 110, 213-228.	0.6	121
160	Dosimetric predictors of biochemical control of prostate cancer in patients randomised to external beam radiotherapy with a boost of high dose rate brachytherapy. <i>Radiotherapy and Oncology</i> , 2014, 110, 110-113.	0.6	18
161	High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity. <i>Radiotherapy and Oncology</i> , 2014, 110, 268-271.	0.6	66
162	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. <i>Lancet Oncology</i> , The, 2014, 15, 1397-1406.	10.7	351

#	ARTICLE	IF	CITATIONS
163	Guidelines for the first line management of classical Hodgkin lymphoma. British Journal of Haematology, 2014, 166, 34-49.	2.5	70
164	Overall response rates to radiation therapy for patients with painful uncomplicated bone metastases undergoing initial treatment and retreatment. Radiotherapy and Oncology, 2014, 112, 125-127.	0.6	16
165	High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer. Radiotherapy and Oncology, 2014, 112, 63-67.	0.6	30
166	Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncology, The, 2014, 15, 164-171.	10.7	239
167	Reirradiation. Cancer Metastasis - Biology and Treatment, 2014, , 341-349.	0.1	0
168	Second primary cancers after radiation for prostate cancer: a review of data from planning studies. Radiation Oncology, 2013, 8, 172.	2.7	39
169	Critical structure movement in cervix brachytherapy. Radiotherapy and Oncology, 2013, 107, 39-45.	0.6	39
170	Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. New England Journal of Medicine, 2013, 369, 213-223.	27.0	2,723
171	Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 281-284.	1.6	32
172	A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. Clinical Cancer Research, 2013, 19, 4879-4888.	7.0	214
173	The Influence of Prostate Volume on Outcome After High-Dose-Rate Brachytherapy Alone for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 270-274.	0.8	21
174	A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer. European Urology, 2013, 63, 189-197.	1.9	154
175	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Annals of Oncology, 2013, 24, 561-576.	1.2	193
176	FTIR microspectroscopy of selected rare diverse subvariants of carcinoma of the urinary bladder. Journal of Biophotonics, 2013, 6, 73-87.	2.3	38
177	Targeted radio-nuclide therapy of skeletal metastases. Cancer Treatment Reviews, 2013, 39, 18-26.	7.7	50
178	Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. Journal of Magnetic Resonance Imaging, 2013, 37, 48-58.	3.4	119
179	Variations in Radiotherapy Delivery in England – Evidence from the National Radiotherapy Dataset. Clinical Oncology, 2013, 25, 531-537.	1.4	16
180	GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update. Radiotherapy and Oncology, 2013, 107, 325-332.	0.6	236

#	ARTICLE	IF	CITATIONS
181	Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiotherapy and Oncology, 2013, 108, 40-47.	0.6	54
182	Recommendations for the Use of Radiotherapy in Nodal Lymphoma. Clinical Oncology, 2013, 25, 49-58.	1.4	56
183	Non-“Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT. Radiology, 2013, 266, 326-336.	7.3	384
184	Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection. Journal of Contemporary Brachytherapy, 2013, 2, 63-69.	0.9	15
185	A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20.. Journal of Clinical Oncology, 2013, 31, 9502-9502.	1.6	2
186	Prostate Brachytherapy: High Dose Rate. , 2013, , 739-748.		1
187	HDR Versus LDR Seeds. , 2013, , 179-186.		0
188	Malignant epidural spinal cord compression. Current Opinion in Supportive and Palliative Care, 2012, 6, 103-108.	1.3	23
189	Recent important developments in the management of nonspine bone metastases. Current Opinion in Supportive and Palliative Care, 2012, 6, 80-84.	1.3	6
190	Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Annals of Oncology, 2012, 23, 231-237.	1.2	68
191	Operable Non-“Small Cell Lung Cancer: Correlation of Volumetric Helical Dynamic Contrast-enhanced CT Parameters with Immunohistochemical Markers of Tumor Hypoxia. Radiology, 2012, 264, 581-589.	7.3	47
192	Bladder conservation for muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2012, 12, 1015-1020.	2.4	5
193	Breast Cancer Risk After Supradiaphragmatic Radiotherapy for Hodgkin's Lymphoma in England and Wales: A National Cohort Study. Journal of Clinical Oncology, 2012, 30, 2745-2752.	1.6	142
194	Update of the International Consensus on Palliative Radiotherapy Endpoints for Future Clinical Trials in Bone Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1730-1737.	0.8	283
195	High-Dose-Rate Brachytherapy Alone for Localized Prostate Cancer in Patients at Moderate or High Risk of Biochemical Recurrence. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1376-1384.	0.8	105
196	Image-guided vulvovaginal interstitial brachytherapy in the treatment of primary and recurrent gynecological malignancies. Brachytherapy, 2012, 11, 306-310.	0.5	24
197	Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy. Leukemia and Lymphoma. 2012. 53. 1949-1952.	1.3	22
198	Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiotherapy and Oncology, 2012, 103, 217-222.	0.6	445

#	ARTICLE	IF	CITATIONS
199	Clinical target volumes in anal cancer: Calculating what dose was likely to have been delivered in the UK ACT II trial protocol. Radiotherapy and Oncology, 2012, 103, 341-346.	0.6	15
200	Prostate post-implant dosimetry: Interobserver variability in seed localisation, contouring and fusion. Radiotherapy and Oncology, 2012, 104, 192-198.	0.6	61
201	Guidelines on the investigation and management of follicular lymphoma. British Journal of Haematology, 2012, 156, 446-467.	2.5	58
202	Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. Journal of Clinical Oncology, 2012, 30, 8-8.	1.6	55
203	Assessment and management of respiratory symptoms of malignant disease. , 2012, , 319-346.		0
204	Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial. Radiotherapy and Oncology, 2011, 100, 86-92.	0.6	309
205	Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting. European Urology, 2011, 59, 477-494.	1.9	642
206	Validation of a Score Predicting Post-Treatment Ambulatory Status After Radiotherapy for Metastatic Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1503-1506.	0.8	42
207	Antivascular Effects of Neoadjuvant Androgen Deprivation for Prostate Cancer: An In Vivo Human Study Using Susceptibility and Relaxivity Dynamic MRI. International Journal of Radiation Oncology Biology Physics, 2011, 80, 721-727.	0.8	54
208	Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline. International Journal of Radiation Oncology Biology Physics, 2011, 79, 965-976.	0.8	765
209	Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors. Cancer Research, 2011, 71, 1805-1815.	0.9	111
210	Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. Journal of Clinical Oncology, 2011, 29, 4096-4104.	1.6	175
211	Bone Metastases. Medical Radiology, 2010, , 191-208.	0.1	0
212	Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. Cancer, 2010, 116, 3670-3673.	4.1	85
213	Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. Journal of Magnetic Resonance Imaging, 2010, 32, 155-164.	3.4	47
214	High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy, 2010, 9, 66-70.	0.5	34
215	Cancer Pain: Part 1: Pathophysiology; Oncological, Pharmacological, and Psychological Treatments: A Perspective from the British Pain Society Endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Medicine, 2010, 11, 742-764.	1.9	100
216	Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. British Journal of Haematology, 2010, 149, 237-243.	2.5	15

#	ARTICLE	IF	CITATIONS
217	Quantitative helical dynamic contrast enhanced computed tomography assessment of the spatial variation in whole tumour blood volume with radiotherapy in lung cancer. Lung Cancer, 2010, 69, 71-76.	2.0	16
218	Radiotherapy for metastatic bone disease: current standards and future prospectus. Expert Review of Anticancer Therapy, 2010, 10, 683-695.	2.4	11
219	Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma. Journal of Clinical Oncology, 2010, 28, 4912-4918.	1.6	264
220	Applicator reconstruction for HDR cervix treatment planning using images from 0.35T open MR scanner. Radiotherapy and Oncology, 2010, 94, 346-352.	0.6	43
221	I-125 seed planning: An alternative method of urethra definition. Radiotherapy and Oncology, 2010, 94, 24-29.	0.6	14
222	Patterns of care for brachytherapy in Europe: Updated results. Radiotherapy and Oncology, 2010, 97, 514-520.	0.6	81
223	Developments in the management of Hodgkin's lymphoma. Lancet, The, 2010, 375, 786-788.	13.7	9
224	Review of intraoperative imaging and planning techniques in permanent seed prostate brachytherapy. Radiotherapy and Oncology, 2010, 94, 12-23.	0.6	102
225	Vascular Disruptive Agents in Combination with Radiotherapy. , 2010, , 231-250.		0
226	Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology, 2009, 27, 5390-5396.	1.6	164
227	Effect of Epoetin Alfa on Survival and Cancer Treatmentâ€‘Related Anemia and Fatigue in Patients Receiving Radical Radiotherapy With Curative Intent for Head and Neck Cancer. Journal of Clinical Oncology, 2009, 27, 5751-5756.	1.6	58
228	Non-surgical treatment of localised prostate cancer. Surgical Oncology, 2009, 18, 255-267.	1.6	3
229	Brachytherapy in the United Kingdom and Spain: a subset analysis of a European pattern of care survey. Clinical and Translational Oncology, 2009, 11, 534-538.	2.4	10
230	Accelerated Radiotherapy, Carbogen, and Nicotinamide (ARCON) in the Treatment of Advanced Bladder Cancer: Mature Results of a Phase II Nonrandomized Study. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1425-1431.	0.8	40
231	The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22. European Journal of Cancer, 2009, 45, 1146-1152.	2.8	108
232	Patientsâ€™ and health care professionalsâ€™ evaluation of health-related quality of life issues in bone metastases. European Journal of Cancer, 2009, 45, 2510-2518.	2.8	50
233	Carbogen and nicotinamide in locally advanced bladder cancer: Early results of a phase-III randomized trial. Radiotherapy and Oncology, 2009, 91, 120-125.	0.6	43
234	Dosimetry and field matching for radiotherapy to the breast and supraclavicular fossa. Radiotherapy and Oncology, 2009, 91, 42-48.	0.6	23

#	ARTICLE	IF	CITATIONS
235	Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer. Radiotherapy and Oncology, 2009, 93, 253-258.	0.6	78
236	Vaginal vault brachytherapy as sole postoperative treatment for low-risk endometrial cancer. Brachytherapy, 2008, 7, 195-199.	0.5	25
237	Prognostic factors for functional outcome and survival after reirradiation for in-field recurrences of metastatic spinal cord compression. Cancer, 2008, 113, 1090-1096.	4.1	77
238	A Phase II Study of High-Dose-Rate Afterloading Brachytherapy as Monotherapy for the Treatment of Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 441-446.	0.8	72
239	A Score Predicting Posttreatment Ambulatory Status in Patients Irradiated for Metastatic Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2008, 72, 905-908.	0.8	80
240	High dose rate brachytherapy for prostate cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2008, 12, 512-514.	1.4	31
241	The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet, The, 2008, 371, 1098-1107.	13.7	1,030
242	Opioids in context: relieving the pain of cancer. The role of comprehensive cancer management. Palliative Medicine, 2008, 22, 303-309.	3.1	10
243	Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no) Tj ETQq1 1 0.784314 rgBT /Overbo FDG-PET Scan after 3 Cycles ABVD. Blood, 2008, 112, 369-369.	1.4	20
244	Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET "negative" after 3 Cycles of ABVD Chemotherapy.. Blood, 2008, 112, 1449-1449.	1.4	1
245	Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study. Journal of the National Cancer Institute, 2007, 99, 206-214.	6.3	411
246	Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm?. Journal of Clinical Oncology, 2007, 25, 5281-5286.	1.6	58
247	Overview of brachytherapy resources in Europe: A survey of patterns of care study for brachytherapy in Europe. Radiotherapy and Oncology, 2007, 82, 50-54.	0.6	33
248	Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiotherapy and Oncology, 2007, 83, 3-10.	0.6	253
249	High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiotherapy and Oncology, 2007, 84, 114-120.	0.6	199
250	Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncology, The, 2007, 8, 111-118.	10.7	105
251	Radiotherapy of metastatic spinal cord compression in very elderly patients. International Journal of Radiation Oncology Biology Physics, 2007, 67, 256-263.	0.8	35
252	Functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary. International Journal of Radiation Oncology Biology Physics, 2007, 67, 532-537.	0.8	39

#	ARTICLE	IF	CITATIONS
253	Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression. International Journal of Radiation Oncology Biology Physics, 2007, 67, 525-531.	0.8	41
254	Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. International Journal of Radiation Oncology Biology Physics, 2007, 67, 417-424.	0.8	78
255	Tumor Antivascular Effects of Radiotherapy Combined with Combretastatin A4 Phosphate in Human Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1375-1380.	0.8	73
256	Improved Posttreatment Functional Outcome is Associated with Better Survival in Patients Irradiated for Metastatic Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1506-1509.	0.8	13
257	Hypoxia in Prostate Cancer: Correlation of BOLD-MRI With Pimonidazole Immunohistochemistry—Initial Observations. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1065-1071.	0.8	169
258	Evaluation of Functional Outcome and Local Control After Radiotherapy for Metastatic Spinal Cord Compression in Patients With Prostate Cancer. Journal of Urology, 2006, 175, 552-556.	0.4	43
259	Defining the appropriate radiotherapy regimen for metastatic spinal cord compression in non-small cell lung cancer patients. European Journal of Cancer, 2006, 42, 1052-1056.	2.8	20
260	Evaluation of the Patient with Bone Metastases at Presentation. , 2006, , 545-554.		0
261	Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients. International Journal of Radiation Oncology Biology Physics, 2006, 64, 182-188.	0.8	57
262	Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1452-1457.	0.8	66
263	An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. International Journal of Radiation Oncology Biology Physics, 2006, 65, 91-99.	0.8	80
264	Is Short-Course Radiotherapy with High Doses per Fraction the Appropriate Regimen for Metastatic Spinal Cord Compression in Colorectal Cancer Patients?. Strahlentherapie Und Onkologie, 2006, 182, 708-712.	2.0	21
265	Short-Course Radiotherapy (RT) for Metastatic Spinal Cord Compression (MSCC) Due to Renal Cell Carcinoma: Results of a Retrospective Multi-Center Study. European Urology, 2006, 49, 846-852.	1.9	22
266	Innovative Technologies in Radiation Therapy: Brachytherapy. Seminars in Radiation Oncology, 2006, 16, 209-217.	2.2	36
267	Quantitative Assessment of Lung Cancer Perfusion Using MDCT: Does Measurement Reproducibility Improve with Greater Tumor Volume Coverage?. American Journal of Roentgenology, 2006, 187, 1079-1084.	2.2	72
268	Lung Cancer Perfusion at Multi-Detector Row CT: Reproducibility of Whole Tumor Quantitative Measurements. Radiology, 2006, 239, 547-553.	7.3	132
269	Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2006, 24, 1590-1596.	1.6	73
270	Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study. Journal of Clinical Oncology, 2006, 24, 1568-1574.	1.6	166

#	ARTICLE	IF	CITATIONS
271	Prognostic Factors for Local Control and Survival After Radiotherapy of Metastatic Spinal Cord Compression. Journal of Clinical Oncology, 2006, 24, 3388-3393.	1.6	292
272	Carbogen and Nicotinamide Increase Blood Flow and 5-Fluorouracil Delivery but not 5-Fluorouracil Retention in Colorectal Cancer Metastases in Patients. Clinical Cancer Research, 2006, 12, 3115-3123.	7.0	35
273	Spinal reirradiation after short-course RT for metastatic spinal cord compression. International Journal of Radiation Oncology Biology Physics, 2005, 63, 872-875.	0.8	79
274	Cervical brachytherapy utilizing ring applicator: Comparison of standard and conformal loading. International Journal of Radiation Oncology Biology Physics, 2005, 63, 934-939.	0.8	34
275	Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. British Journal of Haematology, 2005, 130, 363-372.	2.5	52
276	Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer, 2005, 103, 2287-2297.	4.1	26
277	Evaluation of Five Radiation Schedules and Prognostic Factors for Metastatic Spinal Cord Compression. Journal of Clinical Oncology, 2005, 23, 3366-3375.	1.6	323
278	Radiation Dose in Spinal Cord Compression. Journal of Clinical Oncology, 2005, 23, 8270-8270.	1.6	17
279	Radioisotopes for metastatic bone pain. Lancet Oncology, The, 2005, 6, 353-354.	10.7	4
280	Randomized trial of 8Gy in 1 versus 20Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiotherapy and Oncology, 2005, 75, 54-63.	0.6	233
281	Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology, 2004, 63, 940-945.	1.0	326
282	High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Radiotherapy and Oncology, 2004, 73, 195-198.	0.6	43
283	Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial.. Blood, 2004, 104, 311-311.	1.4	1
284	Quality assurance experience with the randomized neuropathic bone pain trial (Trans-Tasman) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	0.6	13
285	Metastatic spinal cord compression: radiotherapy outcome and dose fractionation. Radiotherapy and Oncology, 2003, 68, 175-180.	0.6	97
286	High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiotherapy and Oncology, 2003, 68, 285-288.	0.6	124
287	The modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen. Radiotherapy and Oncology, 2002, 62, 69-76.	0.6	8
288	International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiotherapy and Oncology, 2002, 64, 275-280.	0.6	300

#	ARTICLE	IF	CITATIONS
289	BOLD MRI of human tumor oxygenation during carbogen breathing. Journal of Magnetic Resonance Imaging, 2001, 14, 156-163.	3.4	175
290	Eligibility audits for the randomized neuropathic bone pain trial (TROG 96.05). Journal of Medical Imaging and Radiation Oncology, 2000, 44, 303-307.	0.6	7
291	A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 96.05). International Journal of Radiation Oncology Biology Physics, 2000, 46, 975-981.	0.8	49
292	High dose rate brachytherapy boost treatment in radical radiotherapy for prostate cancer. Radiotherapy and Oncology, 2000, 57, 285-288.	0.6	27
293	Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma. , 1999, 86, 1322-1328.		38
294	Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiotherapy and Oncology, 1999, 50, 167-171.	0.6	65
295	Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma. Cancer, 1999, 86, 1322-1328.	4.1	8
296	Third Space Sequestration Increases Toxicity of Fludarabine:A Case Report. Acta OncolÃ³gica, 1997, 36, 441-441.	1.8	8
297	Weekly chemotherapy using PMitCEBO in the palliation of recurrent non-Hodgkin's lymphoma. Acta OncolÃ³gica, 1997, 36, 573-576.	1.8	5
298	Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. Radiotherapy and Oncology, 1997, 45, 159-166.	0.6	33
299	The response of human tumors to carbogen breathing, monitored by gradient-recalled echo magnetic resonance imaging. International Journal of Radiation Oncology Biology Physics, 1997, 39, 697-701.	0.8	128
300	Nicotinamide Pharmacokinetics in Normal Volunteers and Patients Undergoing Palliative Radiotherapy. Acta OncolÃ³gica, 1996, 35, 213-219.	1.8	25
301	Administration of nicotinamide during chart: Pharmacokinetics, dose escalation, and clinical toxicity. International Journal of Radiation Oncology Biology Physics, 1995, 32, 1111-1119.	0.8	31
302	Retreatment with radiotherapy for painful bone metastases. International Journal of Radiation Oncology Biology Physics, 1994, 29, 1011-1014.	0.8	98